Abstracts tagged "glucocorticoids and rheumatoid arthritis (RA)"

Abstract Number: 2786 • 2017 ACR/ARHP Annual Meeting
Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Current guidelines recommend holding biologic DMARDs before major surgery, despite limited data. Few studies have examined perioperative timing of individual biologic therapies. This study…
Abstract Number: 1420 • 2017 ACR/ARHP Annual Meeting
The Ability of Patients with Early Rheumatoid Arthritis to Taper Low-Dose Glucocorticoids on Methotrexate Monotherapy and in Combination with Adalimumab
Josef S. Smolen¹, Prashanth Sunkureddi², Jaclyn K. Anderson³, Jenny Griffith³, Dingfeng Jiang³, Kun Chen³, Jessica L. Suboticki⁴ and Arthur Kavanaugh⁵, ¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Clear Lake Rheumatology, Nassau Bay, TX, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Low dose glucocorticoids (GCs) are recommended in combination with ≥1 synthetic DMARDs as part of the initial treatment strategy in rheumatoid arthritis (RA), with…
Abstract Number: 2755 • 2017 ACR/ARHP Annual Meeting
Comparative Risk of Biologic Therapies in Patients with Rheumatoid Arthritis Undergoing Elective Arthroplasty
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic DMARDs have varying mechanisms of action and may be associated with different infection risks. The perioperative time period is a particularly high-risk time…
Abstract Number: 2541 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Use and Low Thoracic Bone Mineral Density Are Predictors for Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
Kenji Mamoto¹, Kentaro Inui², Tadashi Okano¹, Yuko Sugioka³, Masahiro Tada⁴, Tatsuya Koike⁵ and Hiroaki Nakamura⁶, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatology & Orthopaedics, Higashisumiyoshi Morimoto Hospital, Osaka, Japan, ³o, Osaka, Japan, ⁴Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan, ⁵Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, ⁶Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falls and fractures. The…
Abstract Number: 2542 • 2016 ACR/ARHP Annual Meeting
Reducing the Dosage of Glucocorticoid to Zero Might Decrease Risk of Clinical Fractures in Patients with Rheumatoid Arthritis: Five-Year Findings of the Tomorrow Study
Kenji Mamoto¹, Kentaro Inui², Tadashi Okano¹, Yuko Sugioka³, Masahiro Tada⁴, Tatsuya Koike⁵ and Hiroaki Nakamura⁶, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatology & Orthopaedics, Higashisumiyoshi Morimoto Hospital, Osaka, Japan, ³o, Osaka, Japan, ⁴Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan, ⁵Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, ⁶Orthopaedic Surgery, Osaka City University Medical School, Osaka, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) who have muscle weakness and stiff or painful joints might be at increased risk of falls and fractures. The…
Abstract Number: 2544 • 2016 ACR/ARHP Annual Meeting
Glucocorticoid Treatment for 12 Weeks in Early Rheumatoid Arthritis Is Related to an Increase in BMI
Samina A. Turk¹, Linda A. Rasch², Sylvia de Boer¹, Mike T. Nurmohamed^1,3, Willem F. Lems^2,4 and Dirkjan van Schaardenburg^1,5, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁵Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: After the diagnosis of rheumatoid arthritis (RA), glucocorticoids (GCs) are a common initial treatment in addition to methotrexate (MTX)(1). However, many patients are afraid…
Abstract Number: 573 • 2015 ACR/ARHP Annual Meeting
Association Between Three Measures of Oral Glucocorticoid Exposure and Potential Adverse Events Among Patients with Rheumatoid Arthritis
Jennie Best¹, Amanda Farr², Gregory Lenhart², Khaled Sarsour¹, Marni Stott-Miller² and Yong Gil Hwang³, ¹Genentech, South San Francisco, CA, ²Truven Health Analytics, Cambridge, MA, ³Department of Medicine, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Oral glucocorticoids are commonly used to treat rheumatoid arthritis (RA). However, their use may be associated with potential adverse events. Therefore, the objective was…
Abstract Number: 619 • 2015 ACR/ARHP Annual Meeting
Long-Term Adverse Events after Daily Concomitant Treatment with 10mg Prednisone in the 2-Year Computer Assisted Management in Early Rheumatoid Arthritis Trial-II
Maria de Hair, Nicole IJff, Johannes Jacobs and Jacob van Laar, Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
On behalf of the Society for Rheumatology Research Utrecht (SRU) Background/Purpose: To investigate the frequency of long-term adverse events (AEs) in early rheumatoid arthritis (RA)…
Abstract Number: 2033 • 2014 ACR/ARHP Annual Meeting
Patient Factors Associated with Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis
Rachel J. Black^1,2, Rebecca Joseph^2,3, Benjamin Brown⁴, Mohammad Movahedi², Mark Lunt⁵ and William G Dixon², ¹Department of Medicine, The University of Adelaide, Adelaide, Australia, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ⁴Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom
Background/Purpose Oral glucocorticoids (GCs) are commonly used in the treatment of rheumatoid arthritis (RA) and GC prescriptions are often issued in the primary care setting.…
Abstract Number: 2758 • 2013 ACR/ARHP Annual Meeting
Quantifying The Risk Of Incident Type II Diabetes Following Oral Glucocorticoid Therapy In Patients With Rheumatoid Arthritis: Association With Dose and Duration Of Use
William G. Dixon¹, Mohammad Movahedi², Marie-Eve Beauchamp³, David W. Ray⁴ and Michal Abrahamowicz³, ¹The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Institute of Human Development, Institute of Human Development, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Glucocorticoid (GC) therapy is widely used in patients with rheumatoid arthritis (RA). Its association with incident type II diabetes mellitus (DM) is accepted, but…
Abstract Number: 2361 • 2013 ACR/ARHP Annual Meeting
Pharmacokinetic and Pharmacodynamic Characterization Of a Dissociated Agonist Of Glucocorticoid Receptor, Following Multiple Dose Administration In Healthy Japanese Adult Subjects
Brinda Tammara¹, Sou Miyoshi² and Judith Hey-Hadavi³, ¹Pfizer, Collegeville, PA, ²Pfizer, Tokyo, Japan, ³Pfizer, NewYork, NY
Background/Purpose: PF-04171327 is a prodrug of PF-00251802, a dissociated agonist of the glucocorticoid receptor (DAGR) and being developed as treatment for Rheumatoid Arthritis. The objective…
Abstract Number: 1481 • 2013 ACR/ARHP Annual Meeting
Negative Effect Of Glucocorticoids Persistence Therapy On Porosity In Rheumatoid Arthritis Patients Treated With TNFα Blockers
Hubert Marotte¹, Sara Djemouai², Béatrice Pallot-Prades², Hervé Locrelle³ and Thierry Thomas⁴, ¹LBTO INSERM U1059 University Jean Monnet, Saint-Etienne, France, ²University Hospital, Saint-Etienne, France, ³INSERM U1059 and University Hospital, Hôpital Nord, Saint-Etienne, France, ⁴INSERM U1059 and University Hospital, Saint-Etienne, France
Background/Purpose: Rheumatoid arthritis is the most common joint inflammatory disease associated with an increased risk of bone fractures. The standard of therapeutic strategy is to…
Abstract Number: 1216 • 2013 ACR/ARHP Annual Meeting
Risk Factors Associated With Fracture Occurrence Appear to Differ Between Distal Radius, Clinical Vertebral, and Hip Fractures in Japanese Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study
Kensuke Ochi¹, Takefumi Furuya¹, Yuki Go¹, Eisuke Inoue², Katsunori Ikari¹, Atsuo Taniguchi², Hisashi Yamanaka¹ and Shigeki Momohara², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) are at high risk of developing fractures. Previously, utilizing data from our Institute of Rheumatology Rheumatoid Arthritis (IORRA) cohort…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].